HCP 14
Oncology Pharmacist · Germany · Lead pharmacist
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Neutral-to-mixed; highlights dose interruptions and practical management considerations.
Key themes
Pre / post perception
Overall perception shiftNo matched pre/post perception for this HCP
This conversation is not part of the matched pre/post perception sample, so a before-and-after comparison is not available. Their qualitative positions above still reflect what they said at congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“The result is encouraging, but I would want to know which patients benefit most before changing practice.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“My willingness really depends on how practical the monitoring is in a busy clinic.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“I would rather wait for clearer evidence before widening use in this group.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“My instinct after recurrence is to change mechanism of action.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“I would want to see the subgroup detail before it changes my first choice.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“These are events we can manage within normal practice.”